Olink has a unique technology for protein analysis in human protein biomarker research for a more efficient and precise analysis of large numbers of proteins. This technology drives precision medicine by improving the understanding of the interaction of proteins and human disease which is key to improve treatment and patient outcomes across many disease areas.
The field of proteomics has been determined to be one of the most important research areas to fully understand and characterize disease. However, the scientific community has lacked strong technologies and solutions to advance this research over the past decades.
How do we solve it?
Olink’s proprietary Proximity Extension Assay (PEA) technology enables researchers to analyse large numbers of proteins with high-throughput analysis, exceptional data quality, and minimal sample consumption. This enables research that previously could not be done.
How do we improve?
Over the next few years, Olink will scale up operations across markets and applications to drive significant benefits for customers, patients and the research community worldwide.
Olink has experienced rapid growth in recent years and will continue to see high growth for years to come. The company will focus on building an organization that can support the growing global demand from an continuously expanding customer base, as well as continue development of its technology to address additional applications within proteomics.